Spinocerebellar Ataxia Type 3
20
2
4
6
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.0%
2 terminated out of 20 trials
75.0%
-11.5% vs benchmark
5%
1 trials in Phase 3/4
17%
1 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (20)
Umbilical Cord Mesenchymal Stem Cells Therapy (19#iSCLife®-SA) for Patients With Spinocerebellar Ataxia
Troriluzole in Adult Participants With Spinocerebellar Ataxia
A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Instrumented Data Exchange for Ataxia Study
Treatment of Transcranial Alternating Current Stimulation（tACS）on Cerebellar Ataxia
Priming Motor Learning Through Exercise in People With Spinocerebellar Ataxia
STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia
Identification of Biomarkers in Spinocerebellar Ataxia 3
A Pharmacokinetics and Safety Study of BIIB132 in Adults With Spinocerebellar Ataxia 3
Natural History Study of and Genetic Modifiers in Spinocerebellar Ataxias
Efficacy Of Oral Trehalose In Spinocerebellar Ataxia 3
Repetitive Transcranial Magnetic Stimulation in SCA3 Patients
Study of CAD-1883 for Spinocerebellar Ataxia
Neuropsychiatry and Cognition in SCA3/MJD
Natural History of Oculomotor Neurophysiology in Ataxic and Pre-ataxic Carriers of SCA3/MJD
Astrocytic Markers and the Pre-ataxic Period of SCA3/MJD - BIGPRO Study Astrocytes
Safety and Efficacy of Lithium Carbonate in Patients With Spinocerebellar Ataxia Type 3
Pilot Study of Safety and Efficacy of Sodium Phenylbutyrate in Spinocerebellar Ataxia Type 3
Study to Determine the Safety and Tolerability of Varenicline (Chantix®) in Treating Spinocerebellar Ataxia Type 3